Researchers Begin Developing Ovarian Cancer Vaccine

Researchers in the U.K. are working on the first vaccine to prevent ovarian cancer, a groundbreaking public health development. Ovarian cancer remains hard to treat, with a survival rate of only 50% five years post-diagnosis.

 

The vaccine, supported by Cancer Research UK, focuses on women with BRCA1 or BRCA2 gene mutations, who face up to a 45% lifetime risk of developing ovarian cancer. Unlike current prevention methods, which involve invasive surgeries and early menopause, this vaccine aims to train the immune system to detect and attack cancerous cells early. If successful, it could transform cancer prevention strategies globally. Read more in Forbes here.